Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17881884 | 1.00 | RIPK1 (1.00) | RIPK1HCRTR2PRCPFKBP1ALMNA | |
| SCHEMBL20710358 | 0.79 | RIPK1 (0.65) | RIPK1HCRTR2 | |
| SCHEMBL17881986 | 0.76 | RIPK1 (0.80) | RIPK1PRCP | |
| SCHEMBL17881962 | 0.72 | RIPK1 (0.67) | RIPK1 | |
| SCHEMBL17881895 | 0.71 | RIPK1 (0.84) | RIPK1FKBP1A | |
| SCHEMBL17881977 | 0.71 | RIPK1 (0.84) | RIPK1FKBP1A | |
| SCHEMBL19501003 | 0.69 | RIPK1 (0.62) | RIPK1 | |
| SCHEMBL17881971 | 0.68 | RIPK1 (0.82) | RIPK1FKBP1A | |
| SCHEMBL17881960 | 0.68 | RIPK1 (0.71) | RIPK1 | |
| SCHEMBL22608919 | 0.68 | RIPK1 (0.51) | RIPK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885HCRTR2 3813/4885PRCP 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.